199 related articles for article (PubMed ID: 31901591)
1. Review of rituximab in primary CNS lymphoma.
Singh PK; Pan E
J Neurol Sci; 2020 Mar; 410():116649. PubMed ID: 31901591
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract][Full Text] [Related]
3. High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.
DeAtkine AB; Abdelrashid M; Tucker Z; Mehta A; Markert JM; Kim J; Fiveash JB; Oster RA; Lobbous M; Nabors LB
J Neurooncol; 2022 May; 158(1):33-40. PubMed ID: 35441948
[TBL] [Abstract][Full Text] [Related]
4. [Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab].
Shiota Y; Dobashi N; Ito Y; Hosoba R; Yamauchi H; Ishii H; Nakano A; Fukushima R; Ohba R; Yahagi Y; Usui N; Yano S
Rinsho Ketsueki; 2019; 60(2):87-92. PubMed ID: 30842385
[TBL] [Abstract][Full Text] [Related]
5. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
7. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
8. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
[TBL] [Abstract][Full Text] [Related]
9. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
10. Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.
Birnbaum T; Stadler EA; von Baumgarten L; Straube A
J Neurooncol; 2012 Sep; 109(2):285-91. PubMed ID: 22570142
[TBL] [Abstract][Full Text] [Related]
11. Rituximab with high-dose methotrexate in primary central nervous system lymphoma.
Kansara R; Shenkier TN; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D
Am J Hematol; 2015 Dec; 90(12):1149-54. PubMed ID: 26414492
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.
Schmitt AM; Herbrand AK; Fox CP; Bakunina K; Bromberg JEC; Cwynarski K; Doorduijn JK; Ferreri AJM; Illerhaus G; Issa S; Schorb E; Zucca E; Hemkens LG; Schandelmaier S; Kasenda B
Hematol Oncol; 2019 Dec; 37(5):548-557. PubMed ID: 31418878
[TBL] [Abstract][Full Text] [Related]
13. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G
Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800
[TBL] [Abstract][Full Text] [Related]
14. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
[TBL] [Abstract][Full Text] [Related]
15. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
[TBL] [Abstract][Full Text] [Related]
16. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Nagane M
Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
Chen T; Liu Y; Wang Y; Chang Q; Wu J; Wang Z; Geng D; Yu JT; Li Y; Li XQ; Chen H; Zhuang D; Li J; Wang B; Jiang T; Lyu L; Song Y; Qiu X; Li W; Lin S; Zhang X; Lu D; Lei J; Chen Y; Mao Y
J Hematol Oncol; 2022 Sep; 15(1):136. PubMed ID: 36176002
[TBL] [Abstract][Full Text] [Related]
19. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
[TBL] [Abstract][Full Text] [Related]
20. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
